{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:11:25Z","timestamp":1785928285913,"version":"3.56.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s11906-021-01131-y","type":"journal-article","created":{"date-parts":[[2021,3,5]],"date-time":"2021-03-05T16:02:39Z","timestamp":1614960159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Drug Interactions with Antihypertensives"],"prefix":"10.1007","volume":"23","author":[{"given":"Michelle A.","family":"Fravel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,5]]},"reference":[{"key":"1131_CR1","unstructured":"World Health Organization news room fact sheets: hypertension. URL: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension (Accessed 23 Aug 2020)."},{"key":"1131_CR2","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1111\/jch.13364","volume":"20","author":"M Ritchey","year":"2018","unstructured":"Ritchey M, Gillespie C, Wozniak G, et al. Potential need for expanded pharmacologic treatment and lifestyle modification services under the 2017 ACC\/AHA Hypertension Guideline. J Clin Hypertens. 2018;20:1377\u201391.","journal-title":"J Clin Hypertens"},{"key":"1131_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/HYPERTENSIONAHA.119.12907","volume":"74","author":"C Derington","year":"2019","unstructured":"Derington C, Gums T, Bress A, et al. Association of total medication burden with intensive and standard blood pressure control and clinical outcomes: a secondary analysis of SPRINT. Hypertension. 2019;74:267\u201375.","journal-title":"Hypertension."},{"key":"1131_CR4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.amjhyper.2004.01.007","volume":"17","author":"B Carter","year":"2004","unstructured":"\u2022\u2022 Carter B, Lund B, Hayase N, et al. Longitudinal analysis of antihypertensive drug interactions in a medicaid population. Am J Hypertens. 2004;17:421\u20137. This trial established the prevalence of noteworthy antihypertensive drug interactions in the general population.","journal-title":"Am J Hypertens"},{"key":"1131_CR5","unstructured":"Veltassa [package insert]. Redwood City, CA: Relypsa; 2018."},{"key":"1131_CR6","unstructured":"Lokelma [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2020."},{"key":"1131_CR7","unstructured":"Cholestyramine [package insert]. Bridgewater, NJ: Ajanta Phama USA Inc; 2018."},{"key":"1131_CR8","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/clpt.1988.47","volume":"43","author":"N Campbell","year":"1988","unstructured":"Campbell N, Paddock V, Sundaram R. Alteration of methyldopa absorption, metabolism, and blood pressure control caused by ferrous sulfate and ferrous gluconate. Clin Pharmacol Ther. 1988;43:381\u20136.","journal-title":"Clin Pharmacol Ther"},{"key":"1131_CR9","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1517\/14740338.2.6.549","volume":"2","author":"R Maas","year":"2003","unstructured":"Maas R, B\u00f6ger RH. Antihypertensive therapy: special focus on drug interactions. Expert Opin Drug Saf. 2003;2:549\u201379.","journal-title":"Expert Opin Drug Saf"},{"key":"1131_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.2174\/1389200217666160524143843","volume":"17","author":"R Yang","year":"2016","unstructured":"Yang R, Luo Z, Liu Y, Sun M, Zheng L, Chen Y, et al. Drug interactions with angiotensin receptor blockers: role of human cytochromes P450. Curr Drug Metab. 2016;17:681\u201391.","journal-title":"Curr Drug Metab"},{"key":"1131_CR11","first-page":"391","volume":"76","author":"T Lynch","year":"2007","unstructured":"Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:391\u20136.","journal-title":"Am Fam Physician"},{"key":"1131_CR12","unstructured":"US Food & Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers. https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers. Accessed 24 July 2020."},{"key":"1131_CR13","unstructured":"Up-To-Date. Inhibitors and inducers of P-glycoprotein (P-gp) drug efflux pump (P-gp multidrug resistance transporter). https:\/\/www.uptodate.com\/contents\/image\/print?imageKey=EM%2F73326&topicKey=RHEUM%2F1666&source=see_link. Accessed 24 July 2020."},{"key":"1131_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1161\/01.HYP.28.1.109","volume":"28","author":"J Sasseen","year":"1996","unstructured":"Sasseen J, Carter B, Brown T, et al. Comparison of nifedipine alone and in combination with diltiazem or verapamil in hypertension. Hypertension. 1996;28:109\u201314.","journal-title":"Hypertension"},{"key":"1131_CR15","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","volume":"80","author":"P Neuvonen","year":"2006","unstructured":"Neuvonen P, Niemi M, Backman J. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharm Ther. 2006;80:565\u20138.","journal-title":"Clin Pharm Ther"},{"key":"1131_CR16","unstructured":"FDA Drug Safety Announcement: Zocor. URL: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-new-restrictions-contraindications-and-dose-limitations-zocor. Accessed 23 Aug 2020."},{"key":"1131_CR17","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jacc.2019.12.068","volume":"75","author":"B Wiggins","year":"2020","unstructured":"\u2022 Wiggins B, Dixon D, Neyens R, et al. Select drug-drug interactions with direct oral anticoagulants. J Am Coll Card. 2020;75:1341\u201350. This trial provides an overview of potential serious interactions between antihypertensives and DOACs providing guidance on the combined use of these agents that is not currently widely publicized in other references.","journal-title":"J Am Coll Card"},{"key":"1131_CR18","unstructured":"Colcrys [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; 2020."},{"key":"1131_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1097\/HJH.0000000000000758","volume":"4","author":"V Bisognia","year":"2016","unstructured":"Bisognia V, Rossittoa G, Reghin F, et al. Antihypertensive therapy in patients on chronic lithium treatment for bipolar disorders. J Hypertens. 2016;4:20\u20138.","journal-title":"J Hypertens"},{"key":"1131_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1097\/00004714-199602000-00011","volume":"16","author":"PR Finley","year":"1996","unstructured":"Finley PR, O\u2019Brien JG, Coleman RW. Lithium and angiotensin-converting enzyme inhibitors: evaluation of a potential interaction. J Clin Psychopharmacol. 1996;16:68\u201371.","journal-title":"J Clin Psychopharmacol"},{"key":"1131_CR21","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1208\/s12248-016-0023-y","volume":"19","author":"K Ledwitch","year":"2017","unstructured":"Ledwitch K, Roberts A. Cardiovascular ion channel inhibitor drug-drug interactions with P-glycoprotein. AAPS. 2017;19:409\u201320.","journal-title":"AAPS"},{"key":"1131_CR22","unstructured":"Pradaxa [package insert]. Ridgefield, CT. Boehringer Ingelheim Pharmaceuticals, Inc; 2020."},{"key":"1131_CR23","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/S0024-3205(01)01494-1","volume":"70","author":"K Takara","year":"2002","unstructured":"Takara K, Kakumotoa M, Tanigawarab Y, et al. Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002;70:1491\u2013500.","journal-title":"Life Sci"},{"key":"1131_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00059-014-4188-9","volume":"40","author":"C St\u00f6llberger","year":"2015","unstructured":"St\u00f6llberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz. 2015;40:140\u20135.","journal-title":"Herz"},{"key":"1131_CR25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4137\/DTI.S12519","volume":"7","author":"M Amin","year":"2013","unstructured":"Amin M. P-glycoprotein Inhibition for optimal drug delivery. Drug Target Insights. 2013;7:27\u201334.","journal-title":"Drug Target Insights"},{"key":"1131_CR26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bcp.12441","volume":"79","author":"R Shah","year":"2014","unstructured":"\u2022 Shah R, Smith R. Addressing phenoconversion: the Achilles\u2019 heel of personalized medicine. Br J Clin Pharmacol. 2014;79:222\u201340. This review provides an important introduction to phenoconversion, an important phenomenon for future evaluation and management of drug interactions.","journal-title":"Br J Clin Pharmacol"},{"key":"1131_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41397-019-0122-0","volume":"20","author":"M Malki","year":"2020","unstructured":"\u2022 Malki M, Pearson E. Drug\u2013drug\u2013gene interactions and adverse drug reactions. Pharmacogenomics J. 2020;20:355\u201366. This review provides support for ongoing research focused on drug-drug-gene interactions.","journal-title":"Pharmacogenomics J"},{"key":"1131_CR28","doi-asserted-by":"publisher","first-page":"321","DOI":"10.2147\/VHRM.S9989","volume":"6","author":"R D\u00fcsing","year":"2010","unstructured":"D\u00fcsing R. Optimizing blood pressure control through the use of fixed combinations. Vasc Health Risk Manag. 2010;6:321\u20135.","journal-title":"Vasc Health Risk Manag"},{"key":"1131_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.35248\/2157-7609.20.11.244","volume":"11","author":"MI ElAwady","year":"2020","unstructured":"ElAwady MI, Akram W, Sherbash M, et al. Successful clonidine withdrawal in patients receiving cardioselective beta-blockers and beta-blockers with alpha-blocking activity. J Drug Metab Toxicol. 2020;11:244. https:\/\/doi.org\/10.35248\/2157-7609.20.11.244.","journal-title":"J Drug Metab Toxicol"},{"key":"1131_CR30","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007046","volume":"7","author":"C Wilcox","year":"2018","unstructured":"Wilcox C, Shen W, Boulton D, et al. Interaction between the sodium-glucose\u2013linked transporter 2 inhibitor dapagliflozin and the loop diuretic bumetanide in normal human subjects. J Am Heart Assoc. 2018;7:e007046.","journal-title":"J Am Heart Assoc."}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-021-01131-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-021-01131-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-021-01131-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T21:06:10Z","timestamp":1616274370000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-021-01131-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1131"],"URL":"https:\/\/doi.org\/10.1007\/s11906-021-01131-y","relation":{},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"22 September 2020","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"14"}}